← All trials
NCT05199662
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 20, 2022
- Primary completion
- Jan 31, 2024
- Completion date
- May 31, 2024
- First posted
- Jan 20, 2022
- Last posted
- Apr 19, 2022
- Enrollment
- 642
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hospital Moinhos de VentoLead sponsor
- Boehringer IngelheimCollaborator
- BrainomixCollaborator
- Emory UniversityOverall official - principal investigator
- Hospital Moinhos de VentoOverall official - principal investigator
- Government of BrazilCollaborator
- Federal University of Sao PauloOverall official - principal investigator
- Hospital Moinhos de VentoOfficial
- Emory UniversityOfficial
- Federal University of Sao PauloOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.